DK1729821T3 - Sammensætninger og fremgangsmåder til topisk påføring og transdermal afgivelse af botulinumtoksiner - Google Patents

Sammensætninger og fremgangsmåder til topisk påføring og transdermal afgivelse af botulinumtoksiner

Info

Publication number
DK1729821T3
DK1729821T3 DK05731866.9T DK05731866T DK1729821T3 DK 1729821 T3 DK1729821 T3 DK 1729821T3 DK 05731866 T DK05731866 T DK 05731866T DK 1729821 T3 DK1729821 T3 DK 1729821T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
topical application
transdermal delivery
botulinum toxins
Prior art date
Application number
DK05731866.9T
Other languages
English (en)
Inventor
Michael D Dake
Jacob M Waugh
Original Assignee
Revance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics Inc filed Critical Revance Therapeutics Inc
Application granted granted Critical
Publication of DK1729821T3 publication Critical patent/DK1729821T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
DK05731866.9T 2004-03-03 2005-03-03 Sammensætninger og fremgangsmåder til topisk påføring og transdermal afgivelse af botulinumtoksiner DK1729821T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55001504P 2004-03-03 2004-03-03
PCT/US2005/007524 WO2005084410A2 (en) 2004-03-03 2005-03-03 Compositions and methods for topical application and transdermal delivery of botulinum toxins

Publications (1)

Publication Number Publication Date
DK1729821T3 true DK1729821T3 (da) 2013-10-28

Family

ID=34919562

Family Applications (3)

Application Number Title Priority Date Filing Date
DK05731866.9T DK1729821T3 (da) 2004-03-03 2005-03-03 Sammensætninger og fremgangsmåder til topisk påføring og transdermal afgivelse af botulinumtoksiner
DK15185714.1T DK2985039T3 (da) 2004-03-03 2005-03-03 Topisk påføring og transdermal indgivelse af botulinumtoksiner
DK13173674.6T DK2656859T3 (da) 2004-03-03 2005-03-03 Topisk påføring og transdermal tilførsel af botulinumtoksiner

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK15185714.1T DK2985039T3 (da) 2004-03-03 2005-03-03 Topisk påføring og transdermal indgivelse af botulinumtoksiner
DK13173674.6T DK2656859T3 (da) 2004-03-03 2005-03-03 Topisk påføring og transdermal tilførsel af botulinumtoksiner

Country Status (25)

Country Link
US (2) US8398997B2 (da)
EP (3) EP2656859B1 (da)
JP (1) JP5095388B2 (da)
KR (3) KR101322433B1 (da)
CN (2) CN1946431B (da)
AU (1) AU2005218665A1 (da)
BR (1) BRPI0508410B8 (da)
CA (1) CA2558408C (da)
CR (1) CR8602A (da)
CY (1) CY1120816T1 (da)
DK (3) DK1729821T3 (da)
ES (3) ES2554821T3 (da)
HK (4) HK1105774A1 (da)
HU (1) HUE025656T2 (da)
IL (4) IL177816A (da)
LT (1) LT2985039T (da)
MX (2) MX345724B (da)
NO (1) NO20064490L (da)
NZ (1) NZ592041A (da)
PL (1) PL2985039T3 (da)
PT (3) PT2656859E (da)
SG (3) SG10201400339VA (da)
SI (3) SI2985039T1 (da)
TR (1) TR201815364T4 (da)
WO (1) WO2005084410A2 (da)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
JP5610659B2 (ja) * 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 多成分生物学的輸送システム
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
KR20050045946A (ko) 2002-06-25 2005-05-17 애크럭스 디디에스 피티와이 리미티드 비정질 약학적 조성물을 이용한 경피전달속도의 제어
US20120114697A1 (en) 2002-08-19 2012-05-10 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US7824693B2 (en) 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
AU2003279493B2 (en) 2002-10-25 2009-08-20 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US9211248B2 (en) * 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
NZ592041A (en) 2004-03-03 2012-12-21 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
CA2558676C (en) 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US20080220021A1 (en) * 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
AU2013201374B2 (en) * 2005-03-03 2015-05-21 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20070069046A1 (en) * 2005-04-19 2007-03-29 Foamix Ltd. Apparatus and method for releasing a measure of content from a plurality of containers
JP2008540508A (ja) 2005-05-09 2008-11-20 フォーミックス エルティーディー． 起泡性ビヒクル及びその医薬組成物
NZ563946A (en) 2005-06-03 2012-02-24 Acrux Dds Pty Ltd Testosterone containing non-occlusive transdermal drug delivery composition for application to the arm pit / axilla
KR101430767B1 (ko) 2005-07-18 2014-08-19 유니버시티 오브 메사츄세츠 로웰 나노에멀젼 조성물 및 이의 제조 및 사용 방법
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
AU2006315117A1 (en) * 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
ES2710781T3 (es) 2005-12-01 2019-04-26 Univ Massachusetts Lowell Nanoemulsiones de botulinum
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
AU2007215275B2 (en) * 2006-02-10 2013-01-17 The Regents Of The University Of California Transducible delivery of siRNA by dsRNA binding domain fusions to PTD/CPPS
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
KR20150028308A (ko) 2006-12-01 2015-03-13 안테리오스, 인코퍼레이티드 펩티드 나노입자 및 이의 용도
JP2010528981A (ja) 2006-12-01 2010-08-26 アンテリオス， インコーポレイテッド 両親媒性実体ナノ粒子
US20100021502A1 (en) * 2006-12-28 2010-01-28 Waugh Jacob M Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT
MX2009007068A (es) * 2006-12-29 2009-07-10 Revance Therapeutics Inc Composiciones y metodos de aplicacion topica y suministro transdermico de toxinas botulinicas estabilizadas con fragmentos de polipeptido provenientes de hiv-tat.
EP2109363A4 (en) * 2006-12-29 2014-07-09 Revance Therapeutics Inc TRANSPORT MOLECULES USING HIV TAT POLYPEPTIDES WITH REVERSE SEQUENCE
CA2687269C (en) * 2007-05-11 2018-02-20 The Board Of Regents Of The University Of Nebraska Compositions for protein delivery and methods of use thereof
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
NZ582459A (en) * 2007-07-26 2012-05-25 Revance Therapeutics Inc Antimicrobial peptide, compositions, and methods of use
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8617100B2 (en) * 2007-09-04 2013-12-31 Foamix Ltd. Device for delivery of a foamable composition
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009090558A2 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
AU2009223161B2 (en) 2008-03-14 2014-10-30 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
SG10202100698QA (en) * 2008-12-31 2021-02-25 Revance Therapeutics Inc Injectable Botulinum Toxin Formulations
KR20110112381A (ko) * 2008-12-31 2011-10-12 레반스 테라퓨틱스, 아이엔씨. 색소 과다 침착의 치료용 조성물 및 치료 방법
US20120148562A1 (en) 2009-04-01 2012-06-14 Revance Therapeutics, Inc. Methods and compositions for treating skin conditions associated with vascular hyper-reactivity
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
IL268980B (en) * 2009-06-25 2022-09-01 Revance Therapeutics Inc Botulinum toxin formulations without albumin
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011041483A2 (en) * 2009-09-30 2011-04-07 Toxcure, Inc. Use of botulinum neurotoxin to treat substance addictions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
CN102686205A (zh) 2009-10-02 2012-09-19 弗艾米克斯有限公司 局部四环素组合物
WO2011049954A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Compositions comprising wnt modulators or neurotoxins for the treatment of otic disorders
DK2490986T4 (da) * 2009-10-21 2024-06-17 Revance Therapeutics Inc Fremgangsmåder og systemer til oprensning af ikke-kompleksbundet botulinum-neurotoksin
CN102639183B (zh) * 2009-10-30 2016-05-04 雷文斯治疗公司 用于局部施用治疗或美容组合物的装置和方法
CN102762554A (zh) * 2010-02-16 2012-10-31 辉瑞大药厂 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇
EP2889625B1 (en) 2010-03-03 2016-09-14 3M Innovative Properties Company Ligand guanidinyl functionalized polymers
US8978936B2 (en) 2010-07-12 2015-03-17 Foamix Pharmaceuticals Ltd. Apparatus and method for releasing a unit dose of content from a container
US20120294844A1 (en) 2011-01-07 2012-11-22 Revance Therapeutics, Inc. Methods And Kits For Topical Application, Removal, And Inactivation Of Therapeutic Or Cosmetic Toxin Compositions
KR20140003572A (ko) * 2011-01-24 2014-01-09 안테리오스, 인코퍼레이티드 나노입자 조성물
US8791072B2 (en) * 2011-02-28 2014-07-29 Neuro-Ophthalmix, Llc Modulating neuromuscular junction density changes in botulinum-toxin treated tissue
US9498533B2 (en) 2011-04-04 2016-11-22 Board Of Regents Of The University Of Nebraska Drug delivery compositions and methods
CN103702681A (zh) * 2011-07-20 2014-04-02 阿勒根公司 用于治疗脂肪沉积的方法
EP3103472A1 (en) * 2012-03-22 2016-12-14 ReVance Therapeutics, Inc. Method of treatment of wrinkles using topical chemodenervating agents
IN2015DN01765A (da) 2012-08-20 2015-05-29 Univ California
MX370929B (es) * 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
US20140242110A1 (en) * 2013-02-28 2014-08-28 Dt Scimed, Llc Dose, localization, and formulation of botulinum toxins in skin and muscle
EA201690302A1 (ru) 2013-07-30 2016-06-30 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Композиции для местного применения для лечения избыточного потоотделения и способы их применения
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
JP6821866B2 (ja) * 2014-12-08 2021-01-27 ジェイワイエスケイ・スキン・ソリューションズ・プライベイト・リミテッドＪＹＳＫ Ｓｋｉｎ Ｓｏｌｕｔｉｏｎｓ Ｐｔｅ． Ｌｔｄ． 担体分子組成物および関連方法
FR3030524B1 (fr) * 2014-12-17 2017-01-20 Hydro-Fill Utilisation de pll pour ameliorer la stabilite de molecules en solution
KR101876177B1 (ko) * 2016-02-17 2018-07-09 가톨릭관동대학교산학협력단 경피투과 보툴리눔 독소 패치
KR101997474B1 (ko) 2016-06-13 2019-07-09 기초과학연구원 쿠커비투[n]릴을 이용하여 신경전달물질을 제어하는 방법 및 이의 용도
MX2017011630A (es) 2016-09-08 2018-09-25 Foamix Pharmaceuticals Ltd Composiciones y metodos para tratar rosacea y acne.
EP3436054B2 (en) 2016-09-13 2022-07-27 Allergan, Inc. Stabilized non-protein clostridial toxin compositions
WO2018093465A1 (en) 2016-11-21 2018-05-24 Eirion Therapeutics, Inc. Transdermal delivery of large agents
MX2019013716A (es) * 2017-05-18 2020-10-12 Revance Therapeutics Inc Métodos de tratamiento para la distonía cervical.
CN110944677B (zh) 2017-07-21 2023-02-17 上海科技大学 局部组合物及用途
EP3675900A4 (en) 2017-08-28 2021-05-05 Revance Therapeutics, Inc. TRANSMUCOSAL BOTULINUM TOXIN COMPOSITIONS, KITS, AND METHODS FOR TREATMENT OF BLADDER DISORDER
US10918586B2 (en) * 2017-12-07 2021-02-16 Ps Therapy Ltd. Topical compositions and methods of use thereof
JP2021508453A (ja) 2017-12-20 2021-03-11 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ボツリヌス毒素細胞結合ドメインポリペプチドおよび皮膚の若返りのための使用方法
KR102088104B1 (ko) * 2018-06-29 2020-03-11 호서대학교 산학협력단 개망초 꽃 에센셜 오일을 포함하는 신경 근육 관련 질환 예방 및 치료용 조성물
EP3843777A4 (en) 2018-08-28 2022-05-04 Ira Sanders THERAPEUTICS FOR THE SKIN
US20220079873A1 (en) * 2020-09-11 2022-03-17 Ps Therapy Ltd. Topical compositions and methods of use
EP4267163A1 (en) * 2020-12-09 2023-11-01 Dermata Therapeutics, Inc. Compositions for the treatment of skin conditions

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078060A (en) 1976-05-10 1978-03-07 Richardson-Merrell Inc. Method of inducing an estrogenic response
US4434228A (en) 1982-04-20 1984-02-28 Genex Corporation Immobilization of biological materials in condensed polyalkyleneimine polymers
US4816568A (en) 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
JPS63287730A (ja) * 1987-05-20 1988-11-24 Nippon Shokubai Kagaku Kogyo Co Ltd 経皮吸収促進剤およびこれを含有してなる皮膚外用剤
US5252713A (en) 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
US5420105A (en) 1988-09-23 1995-05-30 Gustavson; Linda M. Polymeric carriers for non-covalent drug conjugation
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US5709861A (en) 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
EP1477183B1 (en) 1993-12-28 2005-11-02 Allergan, Inc. Neurotoxic component of Botulinum toxin for modulating cholinergic controlled secretions
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US6986893B2 (en) 1993-12-28 2006-01-17 Allergan, Inc. Method for treating a mucus secretion
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
GB9600272D0 (en) 1996-01-06 1996-03-06 Univ Nottingham Polymers
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
AU734827B2 (en) 1997-05-21 2001-06-21 Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US7150881B2 (en) * 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
US5985434A (en) 1997-11-25 1999-11-16 Kimberly-Clark Worldwide, Inc. Absorbent foam
AU1818299A (en) 1997-12-10 1999-06-28 Washington University Anti-pathogen system and methods of use thereof
WO1999042091A2 (en) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
US6261679B1 (en) 1998-05-22 2001-07-17 Kimberly-Clark Worldwide, Inc. Fibrous absorbent material and methods of making the same
CN1313873A (zh) 1998-07-13 2001-09-19 表达遗传学公司 作为可溶性,生物可降解基因送递载体的聚－l－赖氨酸的聚酯类似物
US6280937B1 (en) 1998-08-14 2001-08-28 Rigel Pharmaceuticals, Inc. Shuttle vectors
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
BR9914891A (pt) 1998-10-27 2001-07-17 Mayo Foundation Processos para aperfeiçoamento de cura de ferimento
US6627632B2 (en) 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US7056656B1 (en) 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
ES2160485B1 (es) 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7008924B1 (en) 1999-07-21 2006-03-07 Amgen, Inc. VGF fusion polypeptides
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6593292B1 (en) 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
US20030104622A1 (en) 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US6544548B1 (en) 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6458763B1 (en) 1999-09-17 2002-10-01 Depuy Orthopeadics Bone sialoprotein-based compositions for enhancing connective tissue repair
US6610820B1 (en) 1999-10-12 2003-08-26 University Of Lausanne Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US6844324B1 (en) 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
US20040109871A1 (en) 2000-01-06 2004-06-10 Pascual David W. M cell directed vaccines
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
US6670322B2 (en) 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20030215412A1 (en) 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20030219462A1 (en) 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
JP5610659B2 (ja) 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 多成分生物学的輸送システム
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US6696038B1 (en) 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
JP2005508832A (ja) 2001-02-16 2005-04-07 セルゲイト， インコーポレイテッド 間隔を開けてアルギニン部分を含むトランスポーター
CA2367636C (en) 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
ES2312651T3 (es) 2001-07-27 2009-03-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Toxina botulinum en el tratamiento o prevencion del acne.
WO2003015698A2 (en) * 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
CA2465886A1 (en) 2001-11-07 2003-05-15 Kathleen S. Crowley Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
CA2469336C (en) 2001-12-11 2013-06-11 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
WO2003102166A2 (en) 2002-02-26 2003-12-11 Maxygen, Inc. Novel flavivirus antigens
CA2476589C (en) * 2002-02-27 2014-02-25 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US7459164B2 (en) * 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
JP2005538954A (ja) 2002-05-31 2005-12-22 トーマス・ジェファーソン・ユニバーシティ 分子の経上皮輸送用組成物及び方法
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7071167B2 (en) 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
US6866856B2 (en) 2002-12-31 2005-03-15 Avon Products, Inc. Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
US7482016B2 (en) 2003-03-19 2009-01-27 The J. David Gladstone Institutes Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides
US20040192754A1 (en) 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
WO2004084839A2 (en) 2003-03-24 2004-10-07 Cady Roger K Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
WO2005030119A2 (en) 2003-04-11 2005-04-07 Allergan, Inc. Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
CA2558676C (en) 2004-03-03 2019-04-16 Essentia Biosystems, Inc. Compositions and methods for topical diagnostic and therapeutic transport
NZ592041A (en) 2004-03-03 2012-12-21 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7691381B2 (en) 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
EP2266600B1 (en) 2004-07-26 2014-09-10 Merz Pharma GmbH & Co. KGaA Therapeutic composition with a botulinum neurotoxin
US20060024331A1 (en) 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins

Also Published As

Publication number Publication date
KR101322433B1 (ko) 2013-10-28
DK2985039T3 (da) 2018-11-19
NO20064490L (no) 2006-10-03
IL253007A0 (en) 2017-08-31
CN1946431B (zh) 2011-12-07
IL237386A (en) 2017-07-31
EP2656859B1 (en) 2015-10-21
MXPA06009898A (es) 2008-02-07
PT2656859E (pt) 2016-02-24
BRPI0508410A (pt) 2007-07-24
HK1105774A1 (en) 2008-02-22
HK1185563A1 (en) 2014-02-21
IL237388A0 (en) 2015-04-30
EP2985039A1 (en) 2016-02-17
JP5095388B2 (ja) 2012-12-12
IL177816A0 (en) 2006-12-31
PT2985039T (pt) 2018-11-09
SI2985039T1 (sl) 2018-12-31
PT1729821E (pt) 2013-10-23
CN1946431A (zh) 2007-04-11
HK1221650A1 (zh) 2017-06-09
SG150568A1 (en) 2009-03-30
BRPI0508410B1 (pt) 2017-05-09
BRPI0508410A8 (pt) 2017-03-14
KR20120091198A (ko) 2012-08-17
SI2656859T1 (sl) 2016-02-29
IL237388A (en) 2017-07-31
SG10201400339VA (en) 2014-05-29
CN102357062B (zh) 2015-08-05
WO2005084410A3 (en) 2006-06-29
CN102357062A (zh) 2012-02-22
AU2005218665A1 (en) 2005-09-15
EP2656859A3 (en) 2014-02-19
IL177816A (en) 2015-02-26
KR101343411B1 (ko) 2013-12-19
KR20070018047A (ko) 2007-02-13
US20050196414A1 (en) 2005-09-08
IL237386A0 (en) 2015-04-30
JP2007526340A (ja) 2007-09-13
BRPI0508410B8 (pt) 2021-05-25
DK2656859T3 (da) 2016-01-11
HK1162952A1 (zh) 2012-09-07
WO2005084410A2 (en) 2005-09-15
TR201815364T4 (tr) 2018-11-21
CR8602A (es) 2007-11-20
ES2431610T3 (es) 2013-11-27
US8404249B2 (en) 2013-03-26
CA2558408A1 (en) 2005-09-15
MX345724B (es) 2017-02-13
CY1120816T1 (el) 2019-12-11
US8398997B2 (en) 2013-03-19
CA2558408C (en) 2014-11-18
SI1729821T1 (sl) 2013-12-31
ES2554821T3 (es) 2015-12-23
WO2005084410A9 (en) 2006-03-16
PL2985039T3 (pl) 2019-01-31
EP1729821B1 (en) 2013-07-17
SG10201803560WA (en) 2018-06-28
ES2691498T3 (es) 2018-11-27
IL253007B (en) 2019-11-28
EP2656859A2 (en) 2013-10-30
KR101330775B1 (ko) 2013-11-18
US20080107690A1 (en) 2008-05-08
EP2985039B1 (en) 2018-08-01
EP1729821A4 (en) 2011-03-16
HUE025656T2 (en) 2016-04-28
LT2985039T (lt) 2018-11-12
KR20130060360A (ko) 2013-06-07
NZ592041A (en) 2012-12-21
EP1729821A2 (en) 2006-12-13

Similar Documents

Publication Publication Date Title
DK1729821T3 (da) Sammensætninger og fremgangsmåder til topisk påføring og transdermal afgivelse af botulinumtoksiner
ZA200707352B (en) Compositions and methods for topical application and transdermal delivery of botulinum toxins
DK1824775T3 (da) Debrideringssammensætning baseret på bromelain og fremgangsmåder til fremstilling deraf
DK1862158T3 (da) Farmaceutisk sammensætning til behandling af depression og fremgangsmåde til fremstilling deraf
EP1948230A4 (en) COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL ADMINISTRATION OF BOTULINUM TOXIN CONTAINING LESS NON-TOXIC PROTEINS
DK2056964T3 (da) Hidtil ukendt molekylsigtesammensætning, fremgangsmåde til fremstilling deraf og fremgangsmåde til anvendelse deraf
DK1830838T3 (da) Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
DK1965763T3 (da) Stabile enzympræparater og fremgangsmåder til anvendelse heraf
DK1781256T3 (da) Phospholipid-gel-sammensætning til lægemiddelafgivelse og fremgangsmåder til behandling af sygdomme ved hjælp af samme
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK1765376T3 (da) Topiske sammensætninger og anvendelse deraf til behandling af epitel-relaterede tilstande
DK2043671T3 (da) Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber
DK1817055T3 (da) Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf
DK1838166T3 (da) Sammensætninger og fremgangsmåder til at forbedre nyrefunktion
DK1778651T3 (da) Multivalente chelatorer til modificering og organisering af target-molekyler
DK2069467T3 (da) Adskillende sammensætninger og fremgangsmåder til anvendelse
DK1986508T3 (da) Fremgangsmåder og sammensætninger til behandling af felin hyperthyroidisme
DK2004295T3 (da) Sammensætning til brandbekæmpelse og formulering af nævnte sammensætning
DK1783105T3 (da) Mørtelsammensætning, fremgangsmåde til fremstilling og anvendelse deraf
IS7572A (is) Aðferð og efni til lækninga
DK1791423T3 (da) Sammensætninger og fremgangsmåder til behandling af hyperproliferative dermatologiske tilstande
DK2046118T3 (da) Herbicidal sammensætning og fremgangsmåde til anvendelse heraf
DK2348867T3 (da) Sammensætning og fremgangsmåde til behandling af cercosporiose i banantræer
SE0400614D0 (sv) Composition and method of treatment